Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., filed a statement of changes in beneficial ownership on November 18, 2026, reporting a share withholding transaction dated November 16, 2026, in connection with the vesting of restricted stock units.
Key Highlights
- Reporting person: Maricel Apuli, identified as Chief Accounting Officer of BridgeBio Pharma, Inc.
- Transaction: 4,714 shares of Common Stock disposed of (code F) at $77.36 per share on November 16, 2026.
- Purpose of withholding: Shares withheld to satisfy the reporting person's tax obligation in connection with the vesting of 9,261 shares of Common Stock underlying RSUs, according to the filing.
- Remaining holdings: Beneficial ownership of Common Stock following the transaction totals 115,973 shares, held directly.
- No derivative securities: The filing reports no derivative security transactions in Table II.
BridgeBio Pharma Chief Accounting Officer Reports RSU Vesting and Share Withholding
According to the filing, Maricel Apuli, serving as Chief Accounting Officer of BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company, disposed of 4,714 shares of Common Stock on November 16, 2026, under transaction code F. The filing describes this as shares withheld by the issuer to cover the reporting person's tax liability arising from the vesting of 9,261 shares of Common Stock underlying restricted stock units. The price recorded for the withheld shares was $77.36 per share.
The filing states that following the reported transaction, Apuli directly holds 115,973 shares of BridgeBio Pharma Common Stock. The transaction was filed by one reporting person and is not noted as an amendment to a prior filing. No box was checked indicating the transaction was made pursuant to a Rule 10b5-1(c) plan. Table II of the filing contains no reported derivative security activity. The form was signed by Maricel Apuli and dated November 17, 2026, with an earliest transaction date of November 16, 2026.
What Was Disclosed
The filing disclosed that BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, had 4,714 shares of Common Stock withheld at $77.36 per share on November 16, 2026, to satisfy taxes on the vesting of 9,261 RSU-underlying shares, leaving her with 115,973 shares directly owned.




Please wait processing your request...